SLUSH2015, Helsinki, Finland, November 11, 2015
Montisera Ltd (“Montisera” or “Company”), a biopharmaceutical company focused on discovering, developing and commercialising novel therapeutics from its platform, announces that it has received positive preclinical efficacy results for the treatment of alcoholism with the Company’s product Montisera_D15, substituted isoquinoline compound developed fully in Finland. The Company gained US and EPO patents for the compound last year.
The tests were performed in Helsinki University. The effects of substituted isoquinolines on alcohol drinking were assessed using the alcohol preferring AA (Alko Alcohol) rats. This model is one of the best models to predict clinical alcohol consumption (Eriksson, 1968).
When Montisera_D15 was given to the animals 30 min prior setting back to cages, the consumption of the alcohol reduced significantly with a dose well tolerated and relevant to the dose expected with humans. “The results are exceptional, and very promising. Montisera wants to proceed now in full force with the required preclinical tests towards the first clinical studies”, says Heikki Vuorikoski, founder and CEO of the company.
About alcohol abuse and dependence
Substance use disorders are a major public health problem. The most common substance of abuse and/or dependence is alcohol. The World Health Organisation estimates that about 140 million people throughout the world suffer from alcohol dependence. In the United States and Western Europe, 10 to 20 percent of men and 5 to 10 percent of women at some point in their lives will meet criteria for alcoholism. Most alcoholics develop alcoholism during adolescence or young adulthood. There is also broad consensus regarding alcoholism as a disease state; the American Medical Association considers alcohol a drug.
About Montisera Ltd
Founded in 2012, Montisera is a biopharmaceutical company focused on discovering, developing and commercialising novel therapeutics from its own and partners’ product platforms in a broad range of disease areas. Montisera utilises a novel drug development strategy, emphasising the power of cooperation between drug development companies, biotechnology companies, academy, individual scientists and investors. The company announced also recently that the Finnish Patent and Registration Office has issued Notice of Allowance for the Company’s product Montisera_D4.1, Finnish Application Serial Number FI20126175 A, “Wood hemicelluloses for use in the treatment of lower urinary tract symptoms and diseases”. Montisera has a pending PCT patent application for the extract.
Eriksson K (1968). Genetic selection for voluntary alcohol consumption in the albino rat. Science 159:739741.
For more information:
CEO Heikki Vuorikoski
tel. +358 40 7562 427 firstname.lastname@example.org
Forward looking statements
This news release may contain forward looking statements that reflect Montisera’s current expectations regarding future events, including statements about whether the subject patent would be issued and adequately protect Montisera against competition, Montisera’s plan to protect the commercial potential of its product candidates, and the future status of pending patent applications. Forward looking statements involve risks and uncertainties. Actual events could differ materially from those projected herein, and depend on a number of factors, including (inter alia) the success of Montisera’s research strategies, the applicability of the discoveries made therein, the successful and timely completion of uncertainties related to the regulatory process, and the acceptance of products by consumer and medical professionals. Existing and prospective investors are cautioned not to place undue reliance on these forward looking statements, which are effective only as of the date hereof. Montisera undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise.